Teva said its 2018 revenue guidance reflected an April launch for the 40 mg dose of Glatopa, but Sandoz and partner Momenta announced FDA approval and the US launch of their less frequently administered Copaxone generic on Feb. 13.
The hits just won't stop coming for Teva Pharmaceutical Industries Ltd., the latest of which is the FDA approval and US launch of Glatopa 40 mg – Sandoz International GMBH's and Momenta Pharmaceuticals Inc.'s less frequently dosed generic formulation of Teva's multiple sclerosis blockbuster Copaxone.
Copaxone (glatiramer acetate) sales already have been hurt by the launch of 20 mg generics and the first approved 40...
The number of viable biotech companies exploiting a particular technology should be limited by intellectual property but the number of biotech IPOs exploiting that same technology always seems greater than those with freedom to operate.
Bimagrumab added to Wegovy increased weight loss and preserved muscle mass, but analysts want to see more safety and efficacy results from a combination with Zepbound.
As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.
